Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Deutsche Börse in connection with its acquisition of Institutional Shareholder Services Inc.
Mandate

Vinge has advised Deutsche Börse in connection with its acquisition of Institutional Shareholder Services Inc.

November 30, 2020 Banking and Finance Employment and Benefits

Vinge has advised Deutsche Börse, one of the world’s largest operators of marketplaces for securities trading, in the Swedish part of the acquisition of a majority holding amounting to approximately 80% of Institutional Shareholder Services Inc., a leading provider of ESG data, steering and analysis to investors.

The acquisition, which values Institutional Shareholder Services Inc. to approximately SEK 20 billion, is conditional upon the salient regulatory approvals and customary conditions to closing.

Vinge’s team primarily consisted of Fredrik Wilkens (responsible partner), Henrik Schön (project manager and regulatory issues), Anton Sjökvist (regulatory issues) and Sara Strandberg (employment law).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025